Overview

Tolera Therapeutics is a Kalamazoo, Michigan based company with novel immune modulating technology.  The technology has application potential in transplantation, oncology, and auto-immune disease, such as Type 1 diabetes or multiple sclerosis.  The technology is based on a monoclonal antibody drug with a novel mechanism of action which offers highly specific targeting of immune cell subsets, permitting safe and targeted modulation; creating an opportunity for immune tolerance.  In contrast, currently used therapies result in broad immune system suppression, often resulting in serious adverse events and toxicities; while offering limited opportunity for immune modulation or tolerance.

Tolera has brought together a team of experienced biotech investors, management, medical and scientific collaborators, to advance the company’s technology through clinical trials and on to market launch.